NCT02588612View on ClinicalTrials.gov

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 1, 2016

Primary Completion Date

August 10, 2020

Study Completion Date

August 10, 2020

Conditions
Neoplasms
Interventions
DRUG

letetresgene autoleucel (GSK3377794)

letetresgene autoleucel (GSK3377794) as an IV infusion.

DRUG

Cyclophosphamide

Cyclophosphamide will be used as a lymphodepleting chemotherapy.

DRUG

Fludarabine

Fludarabine will be used as a lymphodepleting chemotherapy.

Trial Locations (3)

33136

GSK Investigational Site, Miami

33612

GSK Investigational Site, Tampa

77030

GSK Investigational Site, Houston

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02588612 - Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter